SI3072524T1 - Probiotične terapije proti avtizmu - Google Patents

Probiotične terapije proti avtizmu Download PDF

Info

Publication number
SI3072524T1
SI3072524T1 SI201131441T SI201131441T SI3072524T1 SI 3072524 T1 SI3072524 T1 SI 3072524T1 SI 201131441 T SI201131441 T SI 201131441T SI 201131441 T SI201131441 T SI 201131441T SI 3072524 T1 SI3072524 T1 SI 3072524T1
Authority
SI
Slovenia
Prior art keywords
composition
use according
milk
fermented
powder
Prior art date
Application number
SI201131441T
Other languages
English (en)
Inventor
Sarkis K. Mazmanian
Paul H. Patterson
Janet Chow
Elaine Hsiao
Sara Mcbride
Original Assignee
California Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute Of Technology filed Critical California Institute Of Technology
Publication of SI3072524T1 publication Critical patent/SI3072524T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells

Claims (15)

  1. Imenovanje Slovenije pri EP 3 072 524 BI PROBIOTIČNE TERAPIJE PROTI AVTIZMU Patentni zahtevki
    1. Sestava, ki obsega eno samo bakterijo vrste Bacteroides, za uporabo pri zdravljenju posameznika, ki trpi za anksioznostjo, avtizmom, avtistično motnjo spektra, duševnim stanjem z nekaj simptomi iz avtistične motnje spektra, krhkim X sindromom, rettovim sindromom, gomoljo sklerozo, obsesivno kompulzivno motnjo, motnjo pomanjkanja pozornosti, ali shizofrenijo, pri čemer posameznik kaže izboljšano vedenjsko delovanje, pri čemer so bakterijske vrste B fragilis, B. Thetaiotaomicron ali B. vulgatus, in pri čemer je sestava tableta, granula, prašek, kapsula, tekočina ali sestava hrane.
  2. 2. Sestava za uporabo po zahtevku 1, pri čemer omenjena tableta, granula, prašek, kapsula, tekočina ali sestava hrane dalje obsega stabilizator, antioksidant, emulgator, lubrikant, vezivo, krmilnik pH regulatorja ali izotonično sredstvo.
  3. 3. Sestava za uporabo po zahtevku 2, pri čemer omenjeni stabilizator, antioksidant, emulgator, lubrikant, vezivo, krmilnik pH regulatorja ali izotonično sredstvo obsega enega ali več izmed škroba, laktoze, glukoze, saharoze, dekstroze, celuloze, parafina, maščobnokislinskega glicerida, vode, alkohola ali arabskega gumija.
  4. 4. Sestava za uporabo po zahtevku 1, ki dalje obsega enega ali več izmed vitamina C, vitamina E, selena ali cinka.
  5. 5. Sestava za uporabo po zahtevku 1, ki se nahaja v mleku, jogurtu, skuti, siru, nefermentiranem mleku, fermentiranem mleku, fermentiranem izdelku na osnovi mleka, sladoledu, izdelku na osnovi fermentiranih žit, praška na osnovi mleka, formuli za dojenčke, misu, tempehu, tableti iz sojine pijače, tekoči bakterijski suspenziji, posušenem oralnem dopolnilu ali mokrem oralnem dopolnilu.
  6. 6. Sestava za uporabo po zahtevku 1, pri čemer je omenjena sestava hrane mleko, jogurt, skuta, sir, nefermentirano mleko, fermentirano mleko, fermentiran izdelek na osnovi mleka, sladoled, izdelek na osnovi fermentiranih žit prašek na osnovi mleka, formula za dojenčke, miso, tempeh, tableta iz sojine pijače, tekoča bakterijska suspenzija, posušeno oralno dopolnilo ali mokro oralno dopolnilo.
  7. 7. Sestava za uporabo po zahtevkih 1 do 6, pri čemer je omenjena sestava hrane sok ali sojina pijača.
  8. 8. Sestava za uporabo po katerem koli od zahtevkov 1 do 7, pri čemer posameznik kaže znake prepustnosti črevesja.
  9. 9. Sestava za uporabo po katerem koli od zahtevkov 1 do 8, pri čemer izboljšano vedenjsko delovanje obsega znižan nivo anksioznosti ali ponavljajočega se vedenja.
  10. 10. Sestava za uporabo po katerem koli od zahtevkov 1 do 8, pri čemer izboljšano vedenjsko delovanje obsega izboljšano komunikacijo.
  11. 11. Sestava za uporabo po katerem koli od zahtevkov 1 do 8, pri čemer je izboljšano vedenjsko delovanje določeno s standardnim vedenjskim testiranjem.
  12. 12. Sestava za uporabo po katerem koli od zahtevkov 1 do 11, pri čemer je sestava probiotična sestava.
  13. 13. Sestava za uporabo po katerem koli od zahtevkov 1 do 11, pri čemer je sestava nutracevtična sestava.
  14. 14. Sestava za uporabo po katerem koli od zahtevkov 1 do 11, pri čemer je sestava farmacevtska sestava, ki obsega farmacevtsko sprejemljiv nosilec.
  15. 15. Sestava po katerem koli od zahtevkov 1 do 14, pri čemer posameznik trpi za avtistično motnjo spektra.
SI201131441T 2010-10-07 2011-10-06 Probiotične terapije proti avtizmu SI3072524T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39100410P 2010-10-07 2010-10-07
US201161472963P 2011-04-07 2011-04-07
EP16164727.6A EP3072524B1 (en) 2010-10-07 2011-10-06 Probiotic therapies for autism

Publications (1)

Publication Number Publication Date
SI3072524T1 true SI3072524T1 (sl) 2018-04-30

Family

ID=45925310

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131441T SI3072524T1 (sl) 2010-10-07 2011-10-06 Probiotične terapije proti avtizmu

Country Status (15)

Country Link
US (3) US9452189B2 (sl)
EP (2) EP3072524B1 (sl)
JP (2) JP5931884B2 (sl)
CA (1) CA2813606C (sl)
CY (1) CY1120119T1 (sl)
DK (1) DK3072524T3 (sl)
ES (2) ES2581843T3 (sl)
HR (1) HRP20180559T1 (sl)
HU (1) HUE038600T2 (sl)
LT (1) LT3072524T (sl)
PL (1) PL3072524T3 (sl)
PT (1) PT3072524T (sl)
RS (1) RS57006B1 (sl)
SI (1) SI3072524T1 (sl)
WO (1) WO2012048152A2 (sl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20110002965A1 (en) * 2007-11-09 2011-01-06 Round June L Immunomodulating compounds and related compositions and methods
WO2009062132A2 (en) 2007-11-09 2009-05-14 California Institute Of Technology Immunomodulating compounds and related compositions and methods
EP2555753B1 (en) 2010-04-07 2018-08-01 California Institute of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
EP2571982A4 (en) 2010-05-20 2014-01-01 California Inst Of Techn ANTIGEN-SPECIFIC TREGS AND CORRESPONDING COMPOSITIONS, METHODS AND SYSTEMS
WO2012016287A2 (en) 2010-08-04 2012-02-09 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for deuvering them
JP5931884B2 (ja) 2010-10-07 2016-06-08 カリフォルニア インスティチュート オブ テクノロジー 自閉症の生菌療法
EP3610881A1 (en) 2011-03-09 2020-02-19 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
ES2662844T3 (es) 2011-10-03 2018-04-10 California Institute Of Technology Generación de cepa mutante productora solo de PSA
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
EP2890808A4 (en) * 2012-08-29 2016-09-28 California Inst Of Techn DIAGNOSIS AND TREATMENT OF AUTISTICAL DISEASES
EP2994161B1 (en) 2013-05-10 2020-10-28 California Institute of Technology Probiotic prevention and treatment of colon cancer
JP6234331B2 (ja) * 2014-06-13 2017-11-22 森永乳業株式会社 統合失調症治療剤
JP2018502056A (ja) * 2014-10-30 2018-01-25 カリフォルニア インスティチュート オブ テクノロジー 神経発達症群における行動の改善のための細菌含有組成物、及び細菌を使用することを含む、神経発達症群における行動の改善のための方法
EP3212207A4 (en) 2014-10-30 2018-06-13 California Institute of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
JP6800846B2 (ja) * 2014-10-30 2020-12-16 カリフォルニア インスティチュート オブ テクノロジー 神経発達症群における行動の改善のための細菌含有組成物、及び細菌を使用することを含む、神経発達症群における行動の改善のための方法
JP6611156B2 (ja) * 2015-01-30 2019-11-27 史郎 栃谷 妊娠期母体腸内細菌攪乱による行動異常モデル動物の作製方法とその用途
EP3294307A4 (en) 2015-05-14 2019-01-23 Crestovo Holdings Llc COMPOSITIONS FOR TRANSPLANTATION OF FECAL FLORA AND METHODS OF PREPARATION AND USE THEREOF, AND DEVICES FOR THEIR ADMINISTRATION
JP6856968B2 (ja) 2015-05-22 2021-04-14 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 自閉症スペクトラム障害および関連する症候を治療するための方法
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
JP7216998B2 (ja) 2016-03-14 2023-02-02 ホロバイオーム， インコーポレイテッド 中枢神経系の精神障害または疾患を処置するための腸ミクロビオームの改変
US11707493B2 (en) 2016-05-23 2023-07-25 California Institute Of Technology Regulate gut microbiota to treat neurodegenerative disorders
US20170360848A1 (en) * 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
JP2018047146A (ja) * 2016-09-23 2018-03-29 株式会社三共 スロットマシン
JP2018047144A (ja) * 2016-09-23 2018-03-29 株式会社三共 スロットマシン
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
AU2018250206A1 (en) 2017-04-05 2019-10-31 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (PD) and related disorders
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
CA3097521C (en) 2017-05-15 2023-10-17 Axial Biotherapeutics, Inc. Inhibitors of microbially induced amyloid
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
US11168299B2 (en) 2018-04-11 2021-11-09 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11291696B2 (en) 2018-04-11 2022-04-05 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
WO2020069280A1 (en) 2018-09-27 2020-04-02 Crestovo Holdings Llc Compositions and methods for treating epilepsy and related disorders
JP7269568B2 (ja) * 2019-07-12 2023-05-09 コンビ株式会社 不安障害及び／又は気分障害を改善又は予防するための組成物
WO2023120551A1 (ja) * 2021-12-21 2023-06-29 国立大学法人大阪大学 自閉スペクトラム症治療のためのオピオイドの使用
CN114699423B (zh) * 2022-02-16 2023-06-23 广州知易生物科技有限公司 脆弱拟杆菌的荚膜多糖提取物在制备防治精神分裂症的药物中的应用
CN114699424B (zh) * 2022-02-16 2023-07-18 广州知易生物科技有限公司 脆弱拟杆菌两性离子荚膜多糖或/和改性的两性离子荚膜多糖的新应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
US7041814B1 (en) 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
CN1160079C (zh) 1998-03-11 2004-08-04 格勒兰制药株式会社 发泡性肠溶制剂
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20060177424A1 (en) 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
EP1817305A2 (en) 2004-11-16 2007-08-15 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
US20100233312A9 (en) 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
AU2008317000B2 (en) 2007-10-26 2014-10-23 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
EA028911B1 (ru) 2007-11-06 2018-01-31 Биоэлектрон Текнолоджи Корпорейшн ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
CA2711608A1 (en) 2008-01-09 2009-07-16 Yale University Mutations in contaction associated protein 2 (cntnap2) are associated with increased risk for ideopathic autism
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
JP6021187B2 (ja) 2010-04-29 2016-11-09 ウィスコンシン・アルムニ・リサーチ・ファウンデーションＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 自閉症の代謝バイオマーカー
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
AU2011261528A1 (en) 2010-06-01 2013-01-10 Moore Research Enterprises Llc Cellular constituents from Bacteroides, compositions thereof, and therapeutic methods employing Bacteroides or cellular constituents thereof
EP2590658A2 (en) 2010-07-08 2013-05-15 Katholieke Universiteit Leuven Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates
JP5931884B2 (ja) 2010-10-07 2016-06-08 カリフォルニア インスティチュート オブ テクノロジー 自閉症の生菌療法
US20120237482A1 (en) 2011-03-18 2012-09-20 Juan Rodriguez Methods for treatment of neurological disorders by modulation of microglial activation
CN116942833A (zh) 2011-12-01 2023-10-27 国立大学法人 东京大学 诱导调节性t细胞的增殖或积累的人源细菌
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
EP3212207A4 (en) 2014-10-30 2018-06-13 California Institute of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
JP2018502056A (ja) 2014-10-30 2018-01-25 カリフォルニア インスティチュート オブ テクノロジー 神経発達症群における行動の改善のための細菌含有組成物、及び細菌を使用することを含む、神経発達症群における行動の改善のための方法
JP6800846B2 (ja) 2014-10-30 2020-12-16 カリフォルニア インスティチュート オブ テクノロジー 神経発達症群における行動の改善のための細菌含有組成物、及び細菌を使用することを含む、神経発達症群における行動の改善のための方法
JP6856968B2 (ja) 2015-05-22 2021-04-14 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 自閉症スペクトラム障害および関連する症候を治療するための方法
US10200089B2 (en) 2017-06-07 2019-02-05 General Electric Company Sensor system and method

Also Published As

Publication number Publication date
EP2624863B1 (en) 2016-04-20
EP2624863A4 (en) 2014-04-02
EP3072524B1 (en) 2018-01-17
US20160375065A1 (en) 2016-12-29
DK3072524T3 (en) 2018-04-09
US9452189B2 (en) 2016-09-27
JP5931884B2 (ja) 2016-06-08
ES2662412T3 (es) 2018-04-06
PT3072524T (pt) 2018-04-23
HUE038600T2 (hu) 2018-10-29
JP2016185959A (ja) 2016-10-27
HRP20180559T1 (hr) 2018-06-01
PL3072524T3 (pl) 2018-06-29
EP3072524A1 (en) 2016-09-28
ES2581843T3 (es) 2016-09-07
JP6177379B2 (ja) 2017-08-09
US11896629B2 (en) 2024-02-13
WO2012048152A2 (en) 2012-04-12
CY1120119T1 (el) 2018-12-12
US20120087895A1 (en) 2012-04-12
LT3072524T (lt) 2018-03-26
RS57006B1 (sr) 2018-05-31
CA2813606C (en) 2019-01-22
JP2013544780A (ja) 2013-12-19
US20210000888A1 (en) 2021-01-07
EP2624863A2 (en) 2013-08-14
WO2012048152A3 (en) 2012-06-21
CA2813606A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
SI3072524T1 (sl) Probiotične terapije proti avtizmu
Anuyahong et al. Incorporation of anthocyanin-rich riceberry rice in yogurts: Effect on physicochemical properties, antioxidant activity and in vitro gastrointestinal digestion
Breda et al. The importance of the world health organization sugar guidelines for dental health and obesity prevention
de Souza et al. Potential interactions among phenolic compounds and probiotics for mutual boosting of their health-promoting properties and food functionalities–A review
Ahmed et al. Physicochemical quality attributes and antioxidant properties of set-type yogurt fortified with argel (Solenostemma argel Hayne) leaf extract
Baú et al. Changes in soymilk during fermentation with kefir culture: Oligosaccharides hydrolysis and isoflavone aglycone production
Gupta et al. Probiotic fermentation of plant based products: possibilities and opportunities
Nualkaekul et al. Survival of Lactobacillus plantarum in model solutions and fruit juices
WO2009069704A1 (ja) 血中尿酸値低減作用を有する乳酸菌
ROTAR et al. Effect of goji berries and honey on lactic acid bacteria viability and shelf life stability of yoghurt
NZ631085A (en) Infant formula milk powder and preparation method thereof
Randazzo et al. Survival of Lactobacillus rhamnosus probiotic strains in peach jam during storage at different temperatures
Farag et al. Rediscovering acidophilus milk, its quality characteristics, manufacturing methods, flavor chemistry and nutritional value
Almusallam et al. Effect of date palm (Phoenix dactylifera L.) spikelets extract on the physicochemical and microbial properties of set-type yogurt during cold storage
Lim Preparation and functional properties of probiotic and oat-based synbiotic yogurts fermented with lactic acid bacteria
Kemsawasd et al. Survival of probiotics in soyoghurt plus mulberry (cv Chiang Mai 60) leaf extract during refrigerated storage and their ability to tolerate gastrointestinal transit
He et al. An insight into the health beneficial of probiotics dairy products: A critical review
Cătălin et al. Attempts to obtain a new symbiotic product based on soy milk
KR20140072421A (ko) 항스트레스용 조성물
Liu et al. Manufacture and characterization of a novel dairy-free quinoa yogurt fermented by modified commercial starter with Weissella confusa
CN102726737A (zh) 一种全营养餐
CN104522234A (zh) 一种具有降糖功能的食品茶及其制备方法
Maftei et al. New fermented functional product based on soy milk and sea buckthorn syrup
Patrick et al. Development of EPA-DHA microcapsules supplemented probiotic fermented milk
Klobukowski et al. Calcium bioavailability from diets based on white cheese containing probiotics or synbiotics in short-time study in rats